Scarica l'app Stockscreener
0.9677
2.41%
-0.0239
Dopo l'orario di chiusura:
.97
0.0023
+0.24%
Precedente Chiudi:
$0.9916
Aprire:
$0.9971
Volume 24 ore:
642.31K
Relative Volume:
0.86
Capitalizzazione di mercato:
$104.13M
Reddito:
-
Utile/perdita netta:
$-20.31M
Rapporto P/E:
-3.6586
EPS:
-0.2645
Flusso di cassa netto:
$-21.07M
1 W Prestazione:
-1.63%
1M Prestazione:
-0.93%
6M Prestazione:
-19.36%
1 anno Prestazione:
+11.49%
Intervallo 1D:
$0.96
$1.01
Intervallo di 1 settimana:
$0.9201
$1.01
Portata 52W:
$0.3258
$1.51
Oncolytics Biotech Inc Stock (ONCY) Company Profile
Nome
Oncolytics Biotech Inc
Settore
Industria
Telefono
-
Indirizzo
-
Confronta ONCY con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ONCY
Oncolytics Biotech Inc
|
0.9677 | 106.70M | 0 | -20.31M | -21.07M | -0.2645 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.86 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.55 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.29 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
788.49 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.97 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Oncolytics Biotech Inc Stock (ONCY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-13 | Iniziato | Lake Street | Buy |
| 2022-10-06 | Iniziato | Maxim Group | Buy |
| 2021-02-17 | Iniziato | H.C. Wainwright | Buy |
Oncolytics Biotech Inc Borsa (ONCY) Ultime notizie
Oncolytics Biotech plans to shift incorporation from Canada to Nevada - Investing.com
Oncolytics (ONCY) Plans to Shift Incorporation to Nevada for Str - GuruFocus
Oncolytics Biotech plans to shift incorporation from Canada to Nevada By Investing.com - Investing.com South Africa
Oncolytics Biotech Seeks Nevada Domestication to Align with U.S. Growth Strategy - TipRanks
Oncolytics Biotech Inc. Proposes Change of Jurisdiction to Nevada to Enhance U.S. Focus and Strategic Growth - Quiver Quantitative
Oncolytics Biotech® Outlines Strategic Rationale for Proposal to Change Jurisdiction of Incorporation to Nevada - Chartmill
Oncolytics Biotech Inc. - Menafn.com
Is Oncolytics Biotech Inc. stock a contrarian buyInsider Buying & Technical Analysis for Trade Confirmation - ulpravda.ru
Is Oncolytics Biotech Inc. stock a buy for dividend growth - ulpravda.ru
The $170B Survival Race: Why Big Pharma is Snapping Up Late-Stage Cancer Tech - The Manila Times
Oncolytics Biotech®? Provides Update on Intellectual Property Strategy and Patent Filings - MarketScreener
Why Oncolytics Biotech Inc. stock is rated strong buy2025 Valuation Update & Daily Profit Maximizing Trade Tips - ulpravda.ru
Oncolytics Biotech Moves to Extend Pelareorep Patent Runway Beyond 2044 - TipRanks
Oncolytics Biotech files patent application to extend pelareorep protection By Investing.com - Investing.com India
Oncolytics Biotech® Provides Update on Intellectual Property Strategy and Patent Filings - Business Wire
How $594B in Precision Tech is Cracking the Metastatic Cancer Code - Investing News Network
Stocks in play: Oncolytics Biotech Inc - Barchart.com
Oncolytics Biotech expands GI cancer advisory board with three experts By Investing.com - Investing.com Nigeria
Oncolytics Biotech Adds Leading GI Oncologists to Advisory Board as It Prepares Pivotal Pelareorep Trials - TipRanks
Oncolytics Biotech® Expands Its Gastrointestinal Tumor Scientific Advisory Board with the Addition of Dr. Eileen O’Reilly, Dr. Neil Segal, and Dr. Van Morris - Business Wire
Smart Oncology: 5 Stocks Chasing the $317B Prize - The Globe and Mail
What drives Oncolytics Biotech Inc stock priceStock Rotation Strategies & Big Profit Small Investment - earlytimes.in
Oncolytics Biotech Inc. (NASDAQ:ONCY) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Oncolytics Biotech (NASDAQ:ONCY) Shares Down 1.5%Here's Why - MarketBeat
Oncolytics Biotech (R) Publishes Abstract Highlighting Additional Biomarker Analyses at the 2019 American Society of Clinical Oncology Annual Meeting - ACCESS Newswire
Revenue per share of Oncolytics Biotech Inc. – NASDAQ:ONCY - TradingView — Track All Markets
What hedge fund activity signals for Oncolytics Biotech Inc. stockWeekly Profit Recap & Technical Pattern Based Signals - Улправда
Why Oncolytics Biotech Inc. stock is recommended by analystsMarket Growth Report & Real-Time Buy Signal Notifications - Улправда
Published on: 2025-12-20 04:27:06 - Улправда
Will Oncolytics Biotech Inc. stock sustain high P E ratiosMarket Activity Summary & Consistent Return Strategy Ideas - DonanımHaber
Is Oncolytics Biotech Inc. stock trading near support levelsCPI Data & AI Enhanced Trading Signals - DonanımHaber
What analyst consensus says on Oncolytics Biotech Inc. stockJuly 2025 Retail & Reliable Entry Point Trade Alerts - Улправда
Published on: 2025-12-18 16:49:38 - Улправда
Lake Street Remains a Buy on Oncolytics Biotech (ONCY) - The Globe and Mail
[6-K] ONCOLYTICS BIOTECH INC Current Report (Foreign Issuer) | ONCY SEC FilingForm 6-K - Stock Titan
Oncolytics eyes controlled study for pelareorep in colorectal cancer - The Pharma Letter
Oncolytics Biotech® Announces Promising Efficacy and Translational Data Supporting Pelareorep in KRAS-Mutant Metastatic Colorectal Cancer - BioSpace
Immunotherapy Breakthroughs Turn Cold GI Tumors Hot as Market Tops $443B - Cantech Letter
Oncolytics Says Pelareorep Shows 33% Response Rate in Colorectal Cancer Patients; Shares Rise - marketscreener.com
Cancer Drug Developers Secure Regulatory Clarity as FDA Reshapes Approval Standards - GlobeNewswire
Oncolytics rises on additional data for pelareorep in colorectal cancer - Seeking Alpha
Oncolytics reports 33% response rate in hard-to-treat colorectal cancer - Investing.com India
Oncolytics Biotech says data backs pelareorep in KRAS-mutant mCRC - marketscreener.com
Oncolytics Biotech Reports Promising Pelareorep Data in Colorectal Cancer - TipRanks
Oncolytics reports 33% response rate in hard-to-treat colorectal cancer By Investing.com - Investing.com South Africa
Oncolytics Biotech Inc Azioni (ONCY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.90%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):